Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Kodiak Sciences Inc
KOD | US
22.24
USD-0.01
-0.04%
KOD | US
Loading StockChartView...
About Kodiak Sciences Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
23/03/2026
Close
22.24
Open
22.75
High
23.75
Low
21.90
Kodiak Sciences Inc. a clinical stage biopharmaceutical company researches develops and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301) an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD) as well as Phase III clinical study for the treatment of diabetic macular edema naïve macular edema due to retinal vein occlusion and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501 a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601 a triplet biopolymer conjugate for the treatment of dry AMD. The company was formerly known as Oligasis LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto California.
View LessKOD | US
Risk
54.7
Sharpe
4.81
Luna's Score
43/100
Recommendation
Sell
Luna says (KOD | US)
What's Working
Value Stock (Price to Book < 3)
Strong Sharpe Ratio (> 1.2)
What's not Working
Negative Momentum (Declining Price)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
50.0%1 month
54.7%3 months
78.5%6 months
125.7%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
0.89
Debt to equity
0.82
Debt to assets
0.44
Ent. to EBITDA
-0.12
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-192.78M
MarketCap
1.17B
MarketCap(USD)
1.17B
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-71.50
Short ratio
9.18
Short perc.
4.76
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
6.03
Range1M
7.54
Range3M
10.30
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
0.75
Price X volume
10.49M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.12 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 0.89 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 78.54 | 72.80 | Par |
| Debt to Equity | 0.82 | -1.23 | Expensive |
| Debt to Assets | 0.44 | 0.25 | Expensive |
| Market Cap | 1.17B | 3.66B | Emerging |
